Global and China Pancreatic Endocrine Tumor Drug Market Insights, Forecast to 2026

1 Study Coverage

• 1.1 Pancreatic Endocrine Tumor Drug Product Introduction
• 1.2 Market Segments
• 1.3 Key Pancreatic Endocrine Tumor Drug Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Type
  • 1.4.2 Buparlisib Hydrochloride
  • 1.4.3 Dovitinib Lactate
  • 1.4.4 Fosbretabulin Tromethamine
  • 1.4.5 Lanreotide Acetate
  • 1.4.6 MPHE-001B
  • 1.4.7 Others
• 1.5 Market by Application
  • 1.5.1 Global Pancreatic Endocrine Tumor Drug Market Size Growth Rate by Application
  • 1.5.2 Clinic
  • 1.5.3 Research Center
  • 1.5.4 Hospital
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Pancreatic Endocrine Tumor Drug Market Size, Estimates and Forecasts
  • 2.1.1 Global Pancreatic Endocrine Tumor Drug Revenue 2015-2026
  • 2.1.2 Global Pancreatic Endocrine Tumor Drug Sales 2015-2026
• 2.2 Global Pancreatic Endocrine Tumor Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
• 2.3 Pancreatic Endocrine Tumor Drug Historical Market Size by Region (2015-2020)
  • 2.3.1 Global Pancreatic Endocrine Tumor Drug Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.3.2 Global Pancreatic Endocrine Tumor Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
• 2.4 Pancreatic Endocrine Tumor Drug Market Estimates and Projections by Region (2021-2026)
  • 2.4.1 Global Pancreatic Endocrine Tumor Drug Sales Forecast by Region (2021-2026)
  • 2.4.2 Global Pancreatic Endocrine Tumor Drug Revenue Forecast by Region (2021-2026)

3 Global Pancreatic Endocrine Tumor Drug Competitor Landscape by Players

• 3.1 Global Top Pancreatic Endocrine Tumor Drug Sales by Manufacturers
  • 3.1.1 Global Pancreatic Endocrine Tumor Drug Sales by Manufacturers (2015-2020)
  • 3.1.2 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Manufacturers (2015-2020)
• 3.2 Global Pancreatic Endocrine Tumor Drug Manufacturers by Revenue
  • 3.2.1 Global Pancreatic Endocrine Tumor Drug Revenue by Manufacturers (2015-2020)
  • 3.2.2 Global Pancreatic Endocrine Tumor Drug Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Pancreatic Endocrine Tumor Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Pancreatic Endocrine Tumor Drug Revenue in 2019
  • 3.2.5 Global Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Global Pancreatic Endocrine Tumor Drug Price by Manufacturers
• 3.4 Global Pancreatic Endocrine Tumor Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Pancreatic Endocrine Tumor Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Pancreatic Endocrine Tumor Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Pancreatic Endocrine Tumor Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Pancreatic Endocrine Tumor Drug Market Size by Type (2015-2020)
  • 4.1.1 Global Pancreatic Endocrine Tumor Drug Sales by Type (2015-2020)
  • 4.1.2 Global Pancreatic Endocrine Tumor Drug Revenue by Type (2015-2020)
  • 4.1.3 Pancreatic Endocrine Tumor Drug Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Pancreatic Endocrine Tumor Drug Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Pancreatic Endocrine Tumor Drug Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Pancreatic Endocrine Tumor Drug Revenue Forecast by Type (2021-2026)
  • 4.2.3 Pancreatic Endocrine Tumor Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Pancreatic Endocrine Tumor Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global Pancreatic Endocrine Tumor Drug Market Size by Application (2015-2020)
  • 5.1.1 Global Pancreatic Endocrine Tumor Drug Sales by Application (2015-2020)
  • 5.1.2 Global Pancreatic Endocrine Tumor Drug Revenue by Application (2015-2020)
  • 5.1.3 Pancreatic Endocrine Tumor Drug Price by Application (2015-2020)
• 5.2 Pancreatic Endocrine Tumor Drug Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Pancreatic Endocrine Tumor Drug Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Pancreatic Endocrine Tumor Drug Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Pancreatic Endocrine Tumor Drug Price Forecast by Application (2021-2026)

6 China by Players, Type and Application

• 6.1 China Pancreatic Endocrine Tumor Drug Market Size YoY Growth 2015-2026
  • 6.1.1 China Pancreatic Endocrine Tumor Drug Sales YoY Growth 2015-2026
  • 6.1.2 China Pancreatic Endocrine Tumor Drug Revenue YoY Growth 2015-2026
  • 6.1.3 China Pancreatic Endocrine Tumor Drug Market Share in Global Market 2015-2026
• 6.2 China Pancreatic Endocrine Tumor Drug Market Size by Players (International and Local Players)
  • 6.2.1 China Top Pancreatic Endocrine Tumor Drug Players by Sales (2015-2020)
  • 6.2.2 China Top Pancreatic Endocrine Tumor Drug Players by Revenue (2015-2020)
• 6.3 China Pancreatic Endocrine Tumor Drug Historic Market Review by Type (2015-2020)
  • 6.3.1 China Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2015-2020)
  • 6.3.2 China Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2015-2020)
  • 6.3.3 China Pancreatic Endocrine Tumor Drug Price by Type (2015-2020)
• 6.4 China Pancreatic Endocrine Tumor Drug Market Estimates and Forecasts by Type (2021-2026)
  • 6.4.1 China Pancreatic Endocrine Tumor Drug Sales Forecast by Type (2021-2026)
  • 6.4.2 China Pancreatic Endocrine Tumor Drug Revenue Forecast by Type (2021-2026)
  • 6.4.3 China Pancreatic Endocrine Tumor Drug Price Forecast by Type (2021-2026)
• 6.5 China Pancreatic Endocrine Tumor Drug Historic Market Review by Application (2015-2020)
  • 6.5.1 China Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2015-2020)
  • 6.5.2 China Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2015-2020)
  • 6.5.3 China Pancreatic Endocrine Tumor Drug Price by Application (2015-2020)
• 6.6 China Pancreatic Endocrine Tumor Drug Market Estimates and Forecasts by Application (2021-2026)
  • 6.6.1 China Pancreatic Endocrine Tumor Drug Sales Forecast by Application (2021-2026)
  • 6.6.2 China Pancreatic Endocrine Tumor Drug Revenue Forecast by Application (2021-2026)
  • 6.6.3 China Pancreatic Endocrine Tumor Drug Price Forecast by Application (2021-2026)

7 North America

• 7.1 North America Pancreatic Endocrine Tumor Drug Market Size YoY Growth 2015-2026
• 7.2 North America Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
  • 7.2.1 North America Pancreatic Endocrine Tumor Drug Sales by Country (2015-2020)
  • 7.2.2 North America Pancreatic Endocrine Tumor Drug Revenue by Country (2015-2020)
  • 7.2.3 U.S.
  • 7.2.4 Canada

8 Europe

• 8.1 Europe Pancreatic Endocrine Tumor Drug Market Size YoY Growth 2015-2026
• 8.2 Europe Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
  • 8.2.1 Europe Pancreatic Endocrine Tumor Drug Sales by Country
  • 8.2.2 Europe Pancreatic Endocrine Tumor Drug Revenue by Country
  • 8.2.3 Germany
  • 8.2.4 France
  • 8.2.5 U.K.
  • 8.2.6 Italy
  • 8.2.7 Russia

9 Asia Pacific

• 9.1 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size YoY Growth 2015-2026
• 9.2 Asia Pacific Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
  • 9.2.1 Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2015-2020)
  • 9.2.2 Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Region
  • 9.2.3 China
  • 9.2.4 Japan
  • 9.2.5 South Korea
  • 9.2.6 India
  • 9.2.7 Australia
  • 9.2.8 Taiwan
  • 9.2.9 Indonesia
  • 9.2.10 Thailand
  • 9.2.11 Malaysia
  • 9.2.12 Philippines
  • 9.2.13 Vietnam

10 Latin America

• 10.1 Latin America Pancreatic Endocrine Tumor Drug Market Size YoY Growth 2015-2026
• 10.2 Latin America Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
  • 10.2.1 Latin America Pancreatic Endocrine Tumor Drug Sales by Country
  • 10.2.2 Latin America Pancreatic Endocrine Tumor Drug Revenue by Country
  • 10.2.3 Mexico
  • 10.2.4 Brazil
  • 10.2.5 Argentina

11 Middle East and Africa

• 11.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size YoY Growth 2015-2026
• 11.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
  • 11.2.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country
  • 11.2.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Country
  • 11.2.3 Turkey
  • 11.2.4 Saudi Arabia
  • 11.2.5 U.A.E

12 Company Profiles

• 12.1 Ipsen S.A.
  • 12.1.1 Ipsen S.A. Corporation Information
  • 12.1.2 Ipsen S.A. Description and Business Overview
  • 12.1.3 Ipsen S.A. Sales, Revenue and Gross Margin (2015-2020)
  • 12.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Products Offered
  • 12.1.5 Ipsen S.A. Recent Development
• 12.2 Jiangsu Hengrui Medicine Co., Ltd.
  • 12.2.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
  • 12.2.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
  • 12.2.3 Jiangsu Hengrui Medicine Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
  • 12.2.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Products Offered
  • 12.2.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
• 12.3 MediaPharma s.r.l.
  • 12.3.1 MediaPharma s.r.l. Corporation Information
  • 12.3.2 MediaPharma s.r.l. Description and Business Overview
  • 12.3.3 MediaPharma s.r.l. Sales, Revenue and Gross Margin (2015-2020)
  • 12.3.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Products Offered
  • 12.3.5 MediaPharma s.r.l. Recent Development
• 12.4 Novartis AG
  • 12.4.1 Novartis AG Corporation Information
  • 12.4.2 Novartis AG Description and Business Overview
  • 12.4.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
  • 12.4.4 Novartis AG Pancreatic Endocrine Tumor Drug Products Offered
  • 12.4.5 Novartis AG Recent Development
• 12.5 OXiGENE, Inc.
  • 12.5.1 OXiGENE, Inc. Corporation Information
  • 12.5.2 OXiGENE, Inc. Description and Business Overview
  • 12.5.3 OXiGENE, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 12.5.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Products Offered
  • 12.5.5 OXiGENE, Inc. Recent Development
• 12.11 Ipsen S.A.
  • 12.11.1 Ipsen S.A. Corporation Information
  • 12.11.2 Ipsen S.A. Description and Business Overview
  • 12.11.3 Ipsen S.A. Sales, Revenue and Gross Margin (2015-2020)
  • 12.11.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Products Offered
  • 12.11.5 Ipsen S.A. Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter’s Five Forces Analysis
• 13.5 Primary Interviews with Key Pancreatic Endocrine Tumor Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Pancreatic Endocrine Tumor Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details